glp 1 gip receptor agonist The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Physiology and clinical applications of
Description
The GLP-1 activity does not work alone
[DOI] [PMC free article] [PubMed] [Google Scholar] 69.Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB
International Journal of Obesity , 33(9), 956961
The results were promising as the primary composite outcome (first occurrence of three-point MACE) occurred in 608 out of the 4668 patients (13.0%) treated with liraglutide as compared to 694 out of the 4672 patients (14.9%) in the placebo group
Diab Care 37 , 21492158 (2014)
ICH Q1A (R2) : Outlines stability testing requirements, including evaluation of drug-device interactions and environmental stress tolerance
